Skip to main navigation Skip to search Skip to main content

Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024

  • Radhika Gharpure
  • , Carolin Vegvari
  • , Alemseged Abdissa
  • , Yewande Alimi
  • , Assaf Anyamba
  • , Jochen Auerbach
  • , Bernard Bett
  • , Brian H. Bird
  • , Ndeye Sakha Bob
  • , J. Gabrielle Breugelmans
  • , Jessica Clark
  • , Sarah Cleaveland
  • , Jakob Cramer
  • , Jeanette Dawa
  • , Petra C. Fay
  • , Pierre Formenty
  • , Volker Gerdts
  • , Keli N. Gerken
  • , John Gitonga
  • , Martin Groschup
  • James Heighway, Sherry Ama Mawuko Johnson, John Juma, Rebekah C. Kading, Maureen Kamau, Samuel Kerama, Baratang Alison Lubisi, Julius Lutwama, Dick Luyimbazi, Dadi Marami, Sean M. Moore, Mathew Muturi, Grace Mwangoka, Angela Ndiu, M. Kariuki Njenga, Richard Njouom, Luke Nyakarahuka, Serge Nzietchueng, Paul Oloo, Mark Otiende, Samuel Oyola, Lodovico Samuele Paganini, Pranav S. Pandit, Carine Punt, Abdallah M. Samy, Silvia Situma, Heidi Sneddon, Quirine A. ten Bosch, Seda Tezcan-Ulger, Peter N. Thompson, Mike Tildesley, Bachirou Tinto, Juan F. Vesga, Paul P. Wichgers Schreur, Peter Hart
  • Coalition for Epidemic Preparedness Innovations
  • Armauer Hansen Research Institute
  • Africa Centres for Disease Control and Prevention
  • University of Maryland, Baltimore County
  • International Livestock Research Institute
  • University of California at Davis
  • Institut Pasteur de Dakar
  • University of Glasgow
  • University of Nairobi
  • Wellcome Trust
  • World Health Organization
  • University of Saskatchewan
  • University of Liverpool
  • Wellcome Trust Research Laboratories Nairobi
  • Friedrich-Loeffler-Institute
  • Colorado State University
  • Mpala Research Centre
  • Pharmacy and Poisons Board
  • Agricultural Research Council
  • Uganda Virus Research Institute
  • LARISSA II project
  • Haramaya University
  • Fogarty International Center
  • Kenya Zoonotic Disease Unit
  • Ifakara Health Institute
  • Washington State University Global Health Kenya
  • Centre Pasteur du Cameroun
  • Makerere University
  • Food and Agriculture Organization of the United Nations
  • Swissmedic
  • Ain Shams University
  • Wageningen University & Research
  • Mersin University
  • University of Pretoria
  • University of Warwick
  • Health Sciences Research Institute (IRSS)
  • UK Health Security Agency

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Rift Valley fever (RVF) is a zoonotic viral disease that causes epidemics and epizootics among humans and livestock, resulting in substantial health and socioeconomic consequences. Currently, there are no RVF vaccines licensed for humans, but several candidates show promise in early-stage development. Existing gaps in RVF epidemiological data and challenges associated with predicting RVF outbreak risk complicate the planning of efficacy studies, making the pathway to licensure for promising candidates unclear. In June 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) convened a two-day workshop in Nairobi, Kenya, to discuss RVF epidemiology, modeling priorities, and specific gaps relevant to human RVF vaccine development. The workshop included representatives from multiple RVF-endemic countries, key global collaborators, and international health organizations. Workshop participants identified five key priorities: (1) Looking beyond outbreaks: There is a need to better characterize the complex One Health epidemiology of RVF and understand interepidemic persistence of the virus; (2) Better data for better models: Epidemiological modeling is crucial for research, prediction, and planning, but it requires accurate and representative data; (3) New, improved and accessible diagnostics and serological assays: These are needed to inform epidemiology and case definitions, without which RVF research will continue to suffer due to paucity of data and challenges in determining infection and exposure; (4) Defining use cases, regulatory pathways, and implementation strategies for human vaccines: Clarity on these topics will facilitate licensure and effective use of RVF vaccines; and (5) People-centered approaches: Community engagement and involvement of social and behavioral scientists are key to the success of human vaccine research and development and implementation, particularly as the virus impacts livestock and livelihoods. Workshop participants welcomed a renewed focus for RVF epidemiology and modeling, and expressed enthusiasm for continued multidisciplinary collaborations to support enabling sciences for human RVF vaccine research and development.

Original languageEnglish
Article number126860
JournalVaccine
Volume54
DOIs
Publication statusPublished - 30 Apr 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Research and development
  • Rift Valley fever
  • Vaccine development

Fingerprint

Dive into the research topics of 'Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4–5 June 2024'. Together they form a unique fingerprint.

Cite this